Henry Schein Inc.
HSICBusiness Overview
source: coverage-next-full ticker: HSIC step: "01" title: Business Overview — Segments, Model, Strategy created: 2026-05-29
Step 01: Business Overview — Henry Schein, Inc.
Company Description
Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental and medical practitioners. Founded in 1932 in Flushing, New York, the company serves approximately 1 million customers worldwide through a combination of physical product distribution, digital commerce, and software-enabled practice management tools.
The company operates a "value-added distribution" model — going beyond simple product logistics to embed software, financial services, and clinical education into customer workflows, creating stickiness well beyond what a commodity distributor enjoys.
Business Segments
1. Dental Segment (~75% of Revenue)
The Dental segment provides dental practitioners with consumable products, dental equipment, and technology/software solutions. Key sub-verticals:
Consumables (~50% of dental revenue)
- Infection control products (gloves, masks, barriers)
- Impression materials and restorative products
- Anesthetics, cements, and bonding agents
- Lab products and small hand instruments
- Prophylaxis products (prophy paste, polishing cups)
Equipment (~20% of dental revenue)
- Dental chairs, delivery systems, lighting
- Digital imaging (x-ray, CBCT scanners, intraoral cameras)
- Sterilization equipment
- CAD/CAM systems (digital dentistry)
Technology/Software (~30% of dental revenue)
- Henry Schein One (HS1) — umbrella brand for practice management software
- Dentrix — dominant US dental practice management software (300,000+ practitioners)
- Eaglesoft — second major PM platform (acquired from Patterson-era competitor)
- Curve Dental — cloud-native practice management (cloud-first practices)
- Lighthouse 360 — patient communication and recall automation
- Carestream Dental (imaging software components)
- Revenue cycle management (RCM) for dental practices
- Patient engagement and teledentistry tools
Geographic Mix (Dental)
- North America: ~55% of dental segment
- International: ~45% of dental segment (Europe, Australia, Canada primary markets)
2. Medical Segment (~25% of Revenue)
The Medical segment serves office-based physician practices, community health centers, and ambulatory care facilities. Key products:
- Injectable medications and vaccines
- Wound care products
- Diagnostic supplies (glucose monitoring, diagnostic kits)
- Surgical instruments and PPE
- Rehabilitation products
- AED devices and emergency products
Key customers: Primary care physicians, urgent care clinics, community health centers, surgical centers, long-term care facilities.
Competitive position: Top-3 distributor to office-based physicians in the US. Competes primarily with McKesson Medical, Cardinal Health, and Medline.
Business Model
Henry Schein's distribution model operates on two economic pillars:
Product Distribution: High-SKU (~300,000+ SKUs), high-touch distribution to fragmented small-practice customers. HSIC differentiates through field sales representatives ("field sales consultants") who call on dental offices, cross-sell products, and provide clinical education. The sales force creates switching friction beyond what a pure e-commerce competitor can replicate.
Software/Technology: Henry Schein One (HSOne) generates recurring SaaS-like revenue from subscription-based practice management software. This segment enjoys ~80% gross margins vs. ~30% for consumables distribution — the strategic prize driving HSIC's technology investment.
Key Operating Statistics (FY2023)
| Metric | Value |
|---|---|
| Net Revenue | ~$12.35B |
| Countries Operated | 32+ |
| Customers Served | ~1 million |
| Team Schein Members (employees) | ~24,000 |
| Dental Software Users (Dentrix/Eaglesoft) | ~300,000+ practitioners |
| Field Sales Reps | ~5,000+ |
| SKUs Offered | ~300,000+ |
Strategic Priorities
DSO (Dental Service Organization) Penetration: The US dental market is consolidating around DSOs (multi-location dental chains like Heartland Dental, Aspen Dental, Pacific Dental). HSIC has a dedicated DSO sales team and is the preferred distributor for many of the largest DSOs. DSOs are credit-worthy, large-volume purchasers with lower cost-to-serve.
Henry Schein One Expansion: Growing HSOne from point-of-sale practice management to a full "dental operating system" — incorporating patient financing, teledentistry, insurance eligibility, and revenue cycle management. HSOne commands a premium ASP and better margin than product distribution.
Specialty Dental Growth: Orthodontics (clear aligners), implants, and oral surgery are the fastest-growing segments of the dental market. HSIC has been acquiring and investing in specialty distribution and software.
International Expansion: International dental is ~45% of dental segment revenue. Key markets include Germany, UK, Netherlands, France, Australia. Opportunities in emerging dental markets (Brazil, China through partnerships).
Acquisitions: HSIC has historically made 5-10 bolt-on acquisitions per year, primarily in dental distribution, dental software, and specialty products. The 2022 acquisition of Shield Healthcare (home health supplies) and various dental software tuck-ins are examples.
Corporate Governance Overview
- Headquarters: 135 Duryea Road, Melville, New York 11747
- CEO: Stanley Bergman (Chairman & CEO since 1989 — over 35 years)
- CFO: Ronald South (appointed 2022; previously corporate controller)
- Listed: NASDAQ (HSIC)
- Index Membership: S&P 500, NASDAQ-100 (removed 2024)
- Shares Outstanding: ~135 million diluted (FY2024)
Financial Snapshot
source: coverage-next-full ticker: HSIC step: "04" title: Financial Snapshot — 3-Year P&L, Key Metrics created: 2026-05-29
Step 04: Financial Snapshot — 3-Year P&L Summary
Income Statement Summary
| Metric | FY2021 | FY2022 | FY2023 | 3-Yr CAGR |
|---|---|---|---|---|
| Net Revenue | $12,437M | $12,630M | $12,349M | -0.4% |
| Cost of Sales | $8,006M | $8,163M | $7,994M | |
| Gross Profit | $4,431M | $4,467M | $4,355M | -0.9% |
| Gross Margin | 35.6% | 35.4% | 35.3% | |
| Operating Expenses (SG&A) | $3,190M | $3,290M | $3,420M | |
| Restructuring/Cyber Costs | — | — | ~$50M | |
| Operating Income (EBIT) | $1,241M | $1,177M | $885M | -16.2% |
| EBIT Margin | 9.98% | 9.32% | 7.17% | |
| Adj. EBIT (ex-cyber/one-time) | ~$1,241M | ~$1,177M | ~$1,010M | |
| Adj. EBIT Margin | 9.98% | 9.32% | 8.18% | |
| Net Interest Expense | $(62)M | $(86)M | $(121)M | |
| Pre-Tax Income | $1,179M | $1,091M | $764M | |
| Income Tax Expense | $264M | $246M | $191M | |
| Effective Tax Rate | 22.4% | 22.5% | 25.0% | |
| Net Income (GAAP) | $835M | $734M | $478M | -24.4% |
| Net Income Margin | 6.7% | 5.8% | 3.9% | |
| Adj. Net Income (ex-one-time) | ~$835M | ~$734M | ~$640M | |
| Diluted EPS (GAAP) | $5.79 | $5.24 | $3.51 | |
| Adj. Diluted EPS | ~$5.79 | ~$5.58 | ~$4.72 | |
| Diluted Shares Outstanding | 144.2M | 140.1M | 136.2M |
Note: FY2023 GAAP results were heavily impacted by the October 2023 cybersecurity incident. Adjusted figures exclude approximately $150-175M in cyber-related costs (lost revenue impact, recovery expenses, legal/insurance accruals). The effective tax rate was also higher in FY2023 due to unfavorable discrete items.
Adjusted EPS Bridge (FY2022 → FY2023)
| Factor | EPS Impact |
|---|---|
| FY2022 Adj. EPS baseline | $5.58 |
| Organic volume/price improvement | +$0.30 |
| Cyber incident (lost revenue + costs) | -$(1.00) |
| Higher interest expense | -$(0.25) |
| Share count reduction (buybacks) | +$0.12 |
| FX headwind | -$(0.03) |
| FY2023 Adj. EPS | ~$4.72 |
Key Profitability Metrics
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Gross Margin | 35.6% | 35.4% | 35.3% |
| EBIT Margin (adj.) | 9.98% | 9.32% | 8.18% |
| EBITDA Margin (adj.) | 11.5% | 10.8% | 9.7% |
| Net Margin (adj.) | 6.7% | 5.8% | 5.2% |
| FCF Margin | ~4.0% | ~3.5% | ~2.5% |
EBITDA Build
| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Operating Income (Adj.) | $1,241M | $1,177M | $1,010M |
| D&A | $185M | $200M | $210M |
| Stock-Based Compensation | $65M | $70M | $75M |
| Adj. EBITDA | ~$1,491M | ~$1,447M | ~$1,295M |
| Adj. EBITDA Margin | 12.0% | 11.5% | 10.5% |
Revenue Growth Components
| Year | Total Growth | Price/Mix | Volume | FX | M&A |
|---|---|---|---|---|---|
| FY2021 | +18.5% | +3% | +12% | +1% | +2.5% |
| FY2022 | +1.5% | +2% | +1% | -2% | +0.5% |
| FY2023 | -2.2% | +1% | -3% | -1% | +0.8% |
Segment Profitability (Est.)
| Segment | Revenue | Operating Income | Operating Margin |
|---|---|---|---|
| Dental (FY2023) | ~$9.1B | ~$850M | ~9.3% |
| Medical (FY2023) | ~$3.1B | ~$250M | ~8.1% |
| Corporate | — | ~$(90M) | — |
| Total (Adj.) | ~$12.35B | ~$1,010M | ~8.2% |
Note: Dental segment carries the software/technology sub-segment which has margins of 25-30%+ and disproportionately supports the blended dental margin.
Margins vs. Peers
| Company | Gross Margin | EBIT Margin | Context |
|---|---|---|---|
| HSIC | 35.3% | 8.2% (adj.) | Value-added dental dist. + software |
| Patterson (PDCO) | 28.0% | 6.0% | Dental + animal health distributor |
| McKesson (MCK) | 5.0% | 2.5% | Drug distributor (lower margin by nature) |
| Cardinal Health (CAH) | 3.8% | 1.8% | Drug distributor |
| AmerisourceBergen (ABC) | 3.5% | 1.7% | Drug distributor |
HSIC's gross margin premium (35% vs. 28% for PDCO, >30% vs. drug distributors) reflects:
- Higher-value dental products (materials vs. pills)
- Software revenue mix (~15% of revenue at 70%+ gross margins)
- Value-added services bundled into pricing
Working Capital Dynamics
| Metric | FY2022 | FY2023 |
|---|---|---|
| Days Sales Outstanding (DSO) | ~42 days | ~44 days |
| Days Inventory Outstanding (DIO) | ~38 days | ~40 days |
| Days Payable Outstanding (DPO) | ~48 days | ~50 days |
| Cash Conversion Cycle (CCC) | ~32 days | ~34 days |
HSIC's cash conversion cycle is modest for a distributor, though the cyber incident slightly elevated DSO as customers took longer to pay during the disruption period.
Forward Estimates (FY2024E)
| Metric | FY2024E (Consensus) |
|---|---|
| Revenue | ~$12.8B |
| Adj. EBIT | ~$830M-860M |
| Adj. EBIT Margin | ~6.5-6.7% |
| Adj. EPS | ~$4.60-4.90 |
| Adj. EBITDA | ~$1,050-1,080M |
Note: FY2024 consensus assumes continued cyber recovery, some normalization of legal/insurance costs related to cyber, and gradual HSOne subscription growth. The margin outlook is weaker than FY2022 as the company invests in technology/DSO sales infrastructure.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $HSIC.